Share on StockTwits

Shares of GlaxoSmithKline plc (NYSE:GSK) have been given a consensus rating of “Hold” by the seventeen ratings firms that are covering the stock, StockRatingsNetwork reports. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $53.50.

Several analysts have recently commented on the stock. Analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Monday, July 7th. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 2nd. Finally, analysts at Panmure Gordon downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “hold” rating in a research note on Thursday, June 26th.

GlaxoSmithKline plc (NYSE:GSK) traded down 0.15% on Tuesday, hitting $53.50. The stock had a trading volume of 377,845 shares. GlaxoSmithKline plc has a 52 week low of $49.01 and a 52 week high of $56.73. The stock has a 50-day moving average of $53.95 and a 200-day moving average of $54.08. The company has a market cap of $128.8 billion and a P/E ratio of 14.95.

GlaxoSmithKline plc (NYSE:GSK) last announced its earnings results on Wednesday, April 30th. The company reported $0.70 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.72 by $0.02. On average, analysts predict that GlaxoSmithKline plc will post $3.49 earnings per share for the current fiscal year.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.